|
Pfizer affirms again
|
 |
January 8, 2002: 6:26 p.m. ET
Company stands by last month's earnings and 3-year revenue guidance.
|
NEW YORK (CNN/Money) - Drugmaker Pfizer Inc. on Tuesday reaffirmed previous earnings guidance and revenue growth targets ahead of a presentation by its chief financial officer.
In advance of CFO David L. Shedlarz's presentation at the J.P. Morgan Healthcare Conference on Wednesday, Pfizer (PFE: Research, Estimates) said that it stands by last month's forecasts for earnings of at least $1.30 per share and earnings in the range of $1.56-to-$1.60 per share for 2002.
The company also said it still sees double-digit revenue growth for 2003 and 2004 and earnings-per-share growth of 15 percent in those years, excluding certain items.
On average, analysts surveyed by First Call expect Pfizer to earn $1.31 per share with revenues of $31.8 billion in 2001. For 2002 they see earnings per share of $1.59 with revenues of $35.9 billion.
Leading Pfizer's strong 2001 performance is cholesterol-lowering agent Lipitor, the largest-selling drug ever, which is projected to have sales of $6.5 billion, up from $5 billion in 2000. 
|
|
|
|
|
|
|
